Highlighted research articles

In This Issue| January 12 2024 Highlighted research articles Author & Article Information Online ISSN: 2159-8290 Print ISSN: 2159-8274 ©2024 American Association for Cancer Research2024American Association for Cancer Research Cancer Discov (2024) 14 (1): 5–7. https://doi.org/10.1158/2159-8290.CD-14-1-ITI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record January 12 2024 Citation Highlighted research articles. Cancer Discov 1 January 2024; 14 (1): 5–7. https://doi.org/10.1158/2159-8290.CD-14-1-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search The proportion of patients with cancer that benefit from precision oncology remains under debate. Suehnholz and colleagues sought to quantify the expansion of clinical actionability over a 5-year period from 2017 to 2022 by annotating 47,271 clinically sequenced solid tumors for actionable molecular alterations using the OncoKB knowledge base and showed that the fraction of tumors harboring a standard care response biomarker increased (8.9% to 31.6%) while tumors carrying non-actionable drivers were reduced (44.2% to 22.8%). Additionally, frequent alterations in TP53, KRAS, and CDKN2A were observed in tumors with limited or no clinical actionability. These results indicate that progress has been made with precision oncology-based treatment paradigms, but strategies to target currently undruggable oncogenic drivers remain an unmet need. See article, p. 49. Despite the efficacy of Bruton's tyrosine kinase (BTK) inhibitors in B-cell malignancies, relapse occurs over time and therapeutic options for patients with relapsed/refractory disease... You do not currently have access to this content.